Activating mutations in the BCR pathway downstream of BTK, such as in CARD11 or PLCγ2, have also been reported to cause BTKi resistance in MCL [15] as well as DLBCL [30–32]. Here, BCR is linked to diffuse large B-cell lymphoma.